Articles

Poll

Podcasts

Slideshows

Videos

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Fluconazole was linked to improved Mayo and Harvey-Bradshaw scores; Iliev outlines the placebo-controlled trial needed next.

Antifungal Therapy Eased IBD Activity, With Iliyan D. Iliev, PhD

Weill Cornell investigator Iliyan D. Iliev, PhD, explains why fluconazole, not nystatin, cleared gut Candida in IBD.

How Candida Moves From Mouth to Gut in IBD, With Iliyan D. Iliev, PhD

SPY003 cut histologic disease activity by 10 points at 12 weeks, completing proof-of-concept for Spyre's IBD combinations.

SPY003 Meets Primary Endpoint in Phase 2 Trial for Ulcerative Colitis

David T. Rubin, MD, on the screening tools, direct questions, and therapy choices behind IBD's three tiers of remission.

Comprehensive Disease Control Starts With Asking, With David T. Rubin, MD

Gastroenterology in August 2026: RAS inhibitor approval for pancreatic cancer, ABTECT UC data, CRC screening mortality, and GI cancer risk.

6 Gastroenterology Headlines You Missed in August 2026

David T. Rubin, MD, on the questions, screening tools, and system barriers standing between IBD care and the whole patient.

Individualizing IBD Care Beyond the Bowel, With David T. Rubin, MD

A gastroenterologist explains why treating bowel inflammation alone isn't enough to call inflammatory bowel disease "controlled."

What Comprehensive Disease Control Means for IBD, With David Rubin, MD

A gastroenterologist explains why IBD symptoms don't always signal a flare, the biomarkers used to confirm inflammation, and counseling patients through Crohn's disease.

When IBD Symptoms Don't Match Inflammation, With Jordan Axelrad, MD, MPH

Jordan Axelrad, MD, MPH, discusses first-line IBD therapy selection, sequencing after failure, treat-to-target monitoring, and evaluating new agents

Optimizing IBD Treatment and Sequencing, With Jordan Axelrad, MD, MPH

Elizabeth Spencer, MD, discusses new data from 3 birth cohorts linking PFAS metabolites tied to maternal IBD to elevated calprotectin in children.

Same PFAS Metabolites Tied to Maternal IBD Linked to Child Calprotectin

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

Inflammatory Bowel Disease